- Home
- CADL vs OMER Comparison
CADL vs OMER Comparison
Compare CADL & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CADL
- OMER
- Stock Information
- Founded
- CADL 1999
- OMER 1994
- Country
- CADL United States
- OMER United States
- Employees
- CADL 38
- OMER N/A
- Industry
- CADL Biotechnology: Pharmaceutical Preparations
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- CADL Health Care
- OMER Health Care
- Exchange
- CADL Nasdaq
- OMER Nasdaq
- Market Cap
- CADL 252.0M
- OMER 188.1M
- IPO Year
- CADL 2021
- OMER 2009
- Fundamental
- Price
- CADL $5.10
- OMER $3.06
- Analyst Decision
- CADL Strong Buy
- OMER Strong Buy
- Analyst Count
- CADL 5
- OMER 5
- Target Price
- CADL $21.40
- OMER $18.00
- AVG Volume (30 Days)
- CADL 923.7K
- OMER 941.4K
- Earning Date
- CADL 08-12-2025
- OMER 08-06-2025
- Dividend Yield
- CADL N/A
- OMER N/A
- EPS Growth
- CADL N/A
- OMER N/A
- EPS
- CADL N/A
- OMER N/A
- Revenue
- CADL N/A
- OMER N/A
- Revenue This Year
- CADL N/A
- OMER N/A
- Revenue Next Year
- CADL N/A
- OMER $468.75
- P/E Ratio
- CADL N/A
- OMER N/A
- Revenue Growth
- CADL N/A
- OMER N/A
- 52 Week Low
- CADL $3.79
- OMER $2.95
- 52 Week High
- CADL $14.60
- OMER $13.60
- Technical
- Relative Strength Index (RSI)
- CADL 44.91
- OMER 36.97
- Support Level
- CADL $4.73
- OMER $2.95
- Resistance Level
- CADL $5.07
- OMER $3.25
- Average True Range (ATR)
- CADL 0.28
- OMER 0.23
- MACD
- CADL -0.01
- OMER 0.05
- Stochastic Oscillator
- CADL 48.38
- OMER 16.92
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.